Comparison of two oral contraceptives containing either drospirenone or cyproterone acetate in the treatment of hirsutism

Gynecological Endocrinology

Volumn 23, Issue 1, 2007, Pages 38-44

  Batukan, Cem ^a   Muderris, Iptisam Ipek ^a   Ozcelik, Bulent ^a   Ozturk, Ahmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

Cyproterone acetate; Drospirenone; Ethinyl estradiol; Hirsutism; Hyperandrogenism; Oral contraceptive

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; CYPROTERONE ACETATE; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT; PRASTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANDROGEN BLOOD LEVEL; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; FEMALE; HIRSUTISM; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SPOTTING; TESTOSTERONE BLOOD LEVEL; WEIGHT GAIN;

ADOLESCENT; ADULT; ANDROSTENES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HIRSUTISM; HUMANS; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847027994     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09637480601137066     Document Type: Article

References (34)

1. Oláh KS. The modern management of hirsutism. Rev Gynecol Pract 2004;4:211-220.
2. Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril 1990;53:35-39.
3. Azziz R. The evaluation and management of hirsutism. Obstet Gynecol 2003;101:995-1007.
4. Conn JJ, Jacobs HS. The clinical management of hirsutism. Eur J Endocrinol 1997;136:339-348.
5. Barth JH, Cherry CA, Wojnarowska F, Dawber RP. Cyproterone acetate for severe hirsutism: results of a double-blind dose-ranging study. Clin Endocrinol (Oxf) 1991;35:5-10.
6. Kelestimur F, Sahin Y. Comparison of Diane 35 and Diane 35 plus spironolactone in the treatment of hirsutism. Fertil Steril 1998;69:66-69.
7. Lobo RA, Shoupe D, Serafini P, Brinton D, Horton R. The effects of two doses of spironolactone on serum androgens and anagen hair in hirsute women. Fertil Steril 1985;43:200-205.
8. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
9. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R. The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 2002;69:2-15.
10. Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 2004;89:2817-2823.
11. Batukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism. Fertil Steril 2005;85:436-440.
12. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-830.
13. Azziz R. Diagnostic criteria for polycystic ovary syndrome: a reappraisal. Fertil Steril 2005;83:1343-1346.
14. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 2002;17:2495-2499.
15. Ibanez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004;89:1592-1597.
16. McKenna TJ. The use of anti-androgens in the treatment of hirsutism. Clin Endocrinol (Oxf) 1991;35:1-3.
17. Falsetti L, Galbignani E. Long-term treatment with the combination ethinylestradiol and cyproterone acetate in polycystic ovary syndrome. Contraception 1990;42:611-619.
18. Golland IM, Elstein ME. Results of an open one-year study with Diane-35 in women with polycystic ovarian syndrome. Ann N Y Acad Sci 1993;687:263-271.
19. Venturoli S, Marescalchi O, Colombo FM, Macrelli S, Ravaioli B, Bagnoli A, Paradisi R, Flamigni C. A prospective randomized trial comparing low dose flutamide, finasteride, ketoconazole, and cyproterone acetate-estrogen regimens in the treatment of hirsutism. J Clin Endocrinol Metab 1999;84:1304-1310.
20. Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Hum Reprod 2001;16:36-42.
21. Paoletti AM, Lello S, Fratta S, Orru M, Ranuzzi F, Sogliano C, Concas A, Biggio G, Melis GB. Psychological effect of the oral contraceptive formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol. Fertil Steril 2004; 81:645-651.
22. Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 2001;75:496-500.
23. Breitkopf DM, Rosen MP, Young SL, Nagamani M. Efficacy of second versus third generation oral contraceptives in the treatment of hirsutism. Contraception 2003;67:349-353.
24. Murphy A, Cropp CS, Smith BS, Burkman RT, Zacur HA. Effect of low-dose oral contraceptive on gonadotropins, androgens, and sex hormone binding globulin in nonhirsute women. Fertil Steril 1990;53:35-39.
25. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995;80:2559-2563.
26. Vermeulen A, Rubens R. Effects of cyproterone acetate plus ethinylestradiol low dose on plasma androgens and lipids in mildly hirsute or acneic young women. Contraception 1988;38:419-428.
27. Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 1984;63:12-14.
28. Carr BR, Parker CR Jr, Madden JD, MacDonald PC, Porter JC. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab 1979;49:346-349.
29. Calaf-Alsina J, Rodriguez-Espinosa J, Cabero-Roura A, Lenti-Paoli O, Mora-Brugues J, Esteban-Altirriba J. Effects of a cyproterone-containing oral contraceptive on hormonal levels in polycystic ovarian disease. Obstet Gynecol 1987;69:255-258.
30. von Muhlendahl KE, Korth-Schutz S, Muller-Hess R, Helge H, Weber B. Cyproterone acetate and adrenocortical function. Lancet 1977;1:1160-1161.
31. Nader S, Riad-Gabriel MG, Saad MF. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82:3074-3077.
32. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-3168.
33. Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002;17:1729-1737.
34. Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2003;88:148-156.